Patents by Inventor Thomas B. Dschietzig

Thomas B. Dschietzig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKER PREDICTING CORONARY ARTERY DISEASES
    Publication number: 20200371118
    Abstract: Method of determining the health risk for myocardial infartion inpatients subjected to coronary angiography or suspected having an increased cardio-vascular health risk, wherein the concentration of parathyroid hormone is determined in vitro in serum or plasma sample of said patient wherein that the serum or plasma sample is contacted with beads binding oxidized parathyroid hormone and correlating the determined level of parathyroid hormone to the risk for myocardial infarction.
    Type: Application
    Filed: January 17, 2019
    Publication date: November 26, 2020
    Applicant: Immundiagnostik AG
    Inventors: Franz Paul ARMBRUSTER, Thomas B. DSCHIETZIG
  • Method for increasing cardiac inflow by administering a compound that binds RXFP1
    Patent number: 10799561
    Abstract: A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: October 13, 2020
    Assignee: Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
    Inventor: Thomas B. Dschietzig
  • METHOD AND COMPOSITION FOR INCREASING CARDIAC INFLOW
    Publication number: 20190142902
    Abstract: A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.
    Type: Application
    Filed: January 28, 2019
    Publication date: May 16, 2019
    Inventor: Thomas B. Dschietzig
  • Method for treating heart failure with preserved ejection fraction by administering human relaxin-2
    Patent number: 10226512
    Abstract: A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: March 12, 2019
    Assignee: Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
    Inventor: Thomas B. Dschietzig